# EDGAR Filing Document

**Accession Number:** 0000862692
**File Stem:** 0001193125-25-277872
**Filing Date:** 2025-11
**Character Count:** 4217
**Document Hash:** 159217a7edb6e86327776b1c49f10a70
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-277872.hdr.sgml**: 20251112

**ACCESSION NUMBER**: 0001193125-25-277872

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 10

**CONFORMED PERIOD OF REPORT**: 20251112

**ITEM INFORMATION**: Other Events

**FILED AS OF DATE**: 20251112

**DATE AS OF CHANGE**: 20251112

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CRYO CELL INTERNATIONAL INC
- **CENTRAL INDEX KEY:** 0000862692
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 223023093
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1130

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40767
- **FILM NUMBER:** 251473989

**BUSINESS ADDRESS:**
- **STREET 1:** 700 BROOKER CREEK BLVD
- **STREET 2:** SUITE 1800
- **CITY:** OLDSMAR
- **STATE:** FL
- **ZIP:** 34677
- **BUSINESS PHONE:** 813-749-2104

**MAIL ADDRESS:**
- **STREET 1:** 700 BROOKER CREEK BLVD
- **STREET 2:** SUITE 1800
- **CITY:** OLDSMAR
- **STATE:** FL
- **ZIP:** 34677

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## FORM 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** November 12, 2025<br>

------

CRYO-CELL INTERNATIONAL, INC.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-40767 | 22-3023093 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 700 Brooker Creek Blvd.<br>Suite 1800 |  |  |
| Oldsmar**,** Florida |  | 34677 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** 813 749-2100<br>

**,** <br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | |
|:---|:---|
| **<br>Title of each class** | **<br>Name of each exchange on which registered** |
| Common Stock, $0.01 par value<br> CCEL | NYSE American LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 8.01 Other Events.**

Cryo-Cell International, Inc. ("Cryo-Cell") will not declare a quarterly cash dividend for the fourth quarter of fiscal 2025. Cryo-Cell may or may not pay a dividend in future periods, and any future decisions regarding dividend declarations will be based on a variety of factors, including financial performance, capital requirements, and strategic priorities.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | Cryo-Cell International, Inc. |
| Date: | November 12, 2025 | By:  | /s/ David Portnoy |
|  |  |  | David Portnoy, Chairman and Co-CEO |

---

------